FDA clears Kerendia (finerenone) for chronic kidney disease in adults with type 1 diabetes — first new option in more than 30 years.

The U.S. Food and Drug Administration approved Kerendia (finerenone) on 17 September 2026 to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease associated with type 1 diabetes, according to PharmExec and Medscape reports opened for this pack, both citing Bayer’s same-day statement. Soft FLAG: desk did not open a standalone FDA press announcement URL for this sNDA; mechanism and trial figures below are attributed to PharmExec/Medscape/Bayer as opened. Soft FLAG: “first new treatment in more than 30 years” for adult T1D-CKD is Bayer language via those outlets.

The mechanism is mineralocorticoid-receptor blockade with an albuminuria surrogate. Finerenone is a nonsteroidal MRA already marketed for CKD in type 2 diabetes and for certain heart-failure indications; the new label extends it to T1D-CKD by targeting UACR reduction, “which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease,” PharmExec states. Soft FLAG: long-term hard kidney outcomes in T1D are bridged from T2D outcome trials (FIDELIO-DKD, FIGARO-DKD) plus FINE-ONE’s UACR endpoint — surrogate frame, not a desk claim of proven dialysis delay in T1D.

Named actors and evidence as opened sources state them: FINE-ONE (NCT05901831) randomized 242 adults with T1D-CKD to finerenone 10 or 20 mg once daily versus placebo on top of standard care; UACR fell 22% versus placebo at month 3 and 28% at month 6 (averaged primary window across months 3 and 6). Soft FLAG: hyperkalemia occurred in 10.1% on finerenone versus 3.3% on placebo; discontinuation for hyperkalemia 1.7% versus none — PharmExec safety table. Soft FLAG: Dr. Janet McGill (Washington University; FINE-ONE executive committee co-chair) is quoted via Bayer/PharmExec on limited prior options. Soft FLAG: Medscape cites Anne L. Peters, MD (USC), commenting that FINE-ONE is proof-of-concept that finerenone works similarly in T1D and T2D, with potassium monitoring essential and SGLT2 use in T1D limited by DKA risk — independent clinician colour via Medscape.

Company epidemiology colour: Bayer says roughly 20–30% of people in the U.S. with T1D also have CKD. Soft FLAG: company figure via Medscape/PharmExec. Soft FLAG: Priority Review of the supplemental NDA is agency-process colour via PharmExec.

What to watch without mood: label language on potassium monitoring; uptake versus ACE/ARB background therapy; any longer-term eGFR slope publications in T1D beyond the six-month UACR window.

Kerendia’s broader U.S. label already covered CKD associated with type 2 diabetes (kidney and cardiovascular risk reduction) and heart failure with LVEF ≥40% (cardiovascular death, HF hospitalization, urgent HF visits), PharmExec notes, with a July 2025 HF expansion. Soft FLAG: this cut’s motion is the T1D-CKD supplemental clearance, not a restatement of the entire prior label. Soft FLAG: Fine-One results were presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine per PharmExec — publication colour, attribute.

Civilian takeaway without mood: adults with type 1 diabetes and albuminuric CKD now have an FDA-labelled nsMRA option studied in their population, with potassium monitoring as the practical safety gate clinicians already use for the drug in T2D. Soft FLAG: Medscape’s Peters comment underscores DKA limits on SGLT2 use in T1D as context for why an alternate kidney-protective path matters — clinician colour, not a guideline rewrite.

Floor: Kerendia (finerenone) FDA 17 Sep — T1D-CKD UACR indication; FINE-ONE n=242: −22% UACR at 3 mo / −28% at 6 mo vs placebo (opened outlets); first new T1D-CKD therapy in >30 years (Bayer); hyperkalemia watch.